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MicroRNAs (miRNAs) have recently become well‐known efficacious biomarkers
for the diagnosis of diabetic nephropathy (DN). MiRNAs, short noncoding RNAs,
are posttranscriptional regulators of gene expression, which regulate several
biological cell functions, including insulin production and secretion, as well as
insulin resistance in tissues. Today, the focus of the medical world is centered on
the role of miRNAs as mediators for different diseases, such as DN and end‐stage
renal diseases (ESRD). MiRNAs are stable and detectable in human biological
fluids, so their detection for early diagnosis of different diseases is highly
sensitive and specific. Previous reports have shown that the alteration of miRNA
profiles significantly correlates with specific stages of DN, kidney fibrosis,
and renal dysfunction. This review was aimed at assessing the pathway of
different miRNA expressions responsible for insulin secretion disorder and DN
progression.
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1 | DIABETIC NEPHROPATHY
Diabetic nephropathy (DN), one of the microvascular long‐term
outcomes of type 1 and type 2 diabetes mellitus, has shown a
skyrocketing rate of incidence recently. More than 40% of
diabetic patients have end‐stage renal disease (ESRD), requiring
painful and expensive regular dialysis though the mortality rate is
still high. DN is characterized by glomerular hyperfiltration,
nephron enlargement, and mesangial cell hypertrophy, later
progressing to glomerulosclerosis (Bherwani, Saumya, Sandhya,
Patel, & Ghotekar, 2016). Despite the existing published evidence
on the association between circulating microRNAs (miRNAs) and
diabetes or its complications (Guay & Regazzi, 2016; Sebastiani
et al., 2017), there are discrepant results regarding the different
subsets of miRNAs and studies on the precise molecular
mechanisms still remain inconclusive. This review is focused on
the promising role of microRNAs, new mechanistic mediators
in DN.
2 | MicroRNAs
MicroRNAs are small (~21–22 nucleotides), single‐stranded, noncod-
ing RNAs that can regulate gene expression at the posttranscriptional
level through blocking translation or promoting the cleavage of their
target mRNA, leading to its suppression (Gusev, Schmittgen, Lerner,
Postier, & Brackett, 2007; Huang et al., 2011). They can bind to the
sequences of the 3′‐untranslated region (3′‐UTR) in the target mRNA
and interfere with its translation, and yet not disrupt the mRNA. Thirty
percent of human protein‐coding genes have been shown to be
regulated by miRNA, which emphasizes its crucial role in controlling
both biological and pathological functions, including metabolism,
cellular differentiation, proliferation, apoptosis, carcinogenesis, and
tissue development (Lucas & Raikhel, 2013; Shi, Wei, Zhang, & She,
2014). Some of the major functions of miRNA are regulating insulin
synthesis, secretion and sensitivity, differentiating pancreas islet
β‐cells, glucose and lipid metabolism, and insulin resistance (Calderari,
Diawara, Garaud, & Gauguier, 2017; Hennessy, Clynes, Jeppesen, &
J Cell Physiol. 2019;234:42–50.wileyonlinelibrary.com/journal/jcp42 | © 2018 Wiley Periodicals, Inc.
O'Driscoll, 2010). The current advanced technology in detecting
kidney miRNAs including microarrays and quantitative PCRs followed
by generation sequencing has helped researchers in developing
miRNAs as a therapeutic target and a reliable potential biomarker. A
cluster of miRNAs is highly expressed in the kidney, so its role in the
pathogenesis and progression of DN is promising (A. C. Chung, Yu, &
Lan, 2013; Wonnacott, Bowen, & Fraser, 2017).
3 | BIOGENESIS OF miRNA
The process of miRNA biogenesis occurs in both nucleus and
cytoplasm (Oliveto, Mancino, Manfrini, & Biffo, 2017). Initially,
miRNA genes are transcripted by RNA polymerase II; then,
primary transcripts (pri‐miRNAs) are capped and polyadenylated
(X. Chen, Li, Guo, Zhang, & Zeng, 2017; Olejniczak, Kotowska‐
Zimmer, & Krzyzosiak, 2018). The pri‐miRNAs with several
hairpin‐like structures form the stem‐loop precursor of miRNAs
(~70 nucleotides long), which is modified by the ribonuclease III
(Drosha) in a microprocessor complex or by DiGeorge syndrome
critical region gene 8 (DGCR8). Subsequently, Ran‐GTP/exportin 5
complex transfers pre‐miRNAs from the nucleus to the cytoplasm
(Kato, Castro, & Natarajan, 2013). In the cytoplasm, more cleavage
might occur in the pri‐miRNA stem‐loop structure by Dicer,
another RNase III enzyme, and its cofactor, TAR RNA‐binding
protein. Finally, the duplex miRNAs with approximately 22 base
pair double‐strand RNAs are generated. The next step will be
loading the miRNA strand (guide strand) into the RNA‐induced
silencing complex (RISC), while the other strand is rapidly
degraded. The RISC complex is a multiprotein complex including
the Argonaute (Ago) family and the mature miRNA, which is
necessary for miRNA‐mediated gene silencing. The miRNA‐RISC
can be the specified binding sites within the 3′‐UTR of the target
mRNA, depending on the degree of complementarily between the
miRNA and the target mRNA transcript; so miRNAs can help with
translational repression, protein synthesis inhibition, and acceler-
ated transcript degradation through uncapping and deadenylation
or mRNA cleavage (Kato & Natarajan, 2015; McClelland &
Kantharidis, 2014; Natarajan, Putta, & Kato, 2012) (Figure 1).
4 | DIABETES AND miRNAs
The family of miRNAs has been found to have a major contribution in
alteration of gene expression and is involved in β‐cells dysfunction and
insulin resistance. Current evidence show that miRNAs can play a role
in regulating glucose hemostasis, through modifying the β‐cell insulin‐
producing function, insulin secretion and signaling pathways of insulin
functions in peripheral tissues such as liver, muscle, and adipose tissue
(LaPierre & Stoffel, 2017; Shi, Zhao et al., 2014). Initially, the beneficial
impacts of miRNAs were identified for different cancers. However,
recently there has been a huge interest toward their application in other
diseases, including diabetes (Sebastiani et al., 2017). Moreover, miRNA‐
30d (miR‐30d), one of the miRNAs, may be upregulated by glucose,
which induces insulin gene expression in β‐cells. Also, overexpression of
miR‐30d protects β‐cells against tumor necrosis factor (TNF) suppres-
sing function in both insulin gene expression and insulin secretion (L. Liu,
Lin, Zhang, Cao, & Liu, 2016; Tang, Muniappan, Tang, & Ozcan, 2009).
F IGURE 1 Biogenesis of miRNA [Color figure can be viewed at wileyonlinelibrary.com]
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5 | MiRNAs AND INSULIN SECRETION
Some miRNAs can target genes involved in pancreas development,
β‐cell proliferation, insulin secretion, and, eventually, insulin exocy-
tose (Lu, Fei, Yang, Xu, & Li, 2015). For example, microRNA‐30d
(miR‐30d), one of the miRNAs upregulated by glucose, can induce
insulin gene expression in pancreatic cells. Therefore, high expression
of miR‐30d protects β‐cells against the suppressing effects of TNF. It
effects on both insulin transcription and insulin secretion, through
downregulating mitogen‐activated protein kinase 4 (MAP4K4) (Tang
et al., 2009; Xie et al., 2011). Previous studies have shown that in the
islets of diabetic db/db mice, in which the MAP4K4 expression level
is elevated, the miR‐30d expression is decreased (Zhao, Mohan,
Ozcan, & Tang, 2012). Hence, miRNA expression is crucial for
accurate pancreatic islet development. For example, the expression
of miR‐375, one of the most abundant miRNAs in islet cells, is
managed by pancreatic and duodenal homeobox 1 (Pdx‐1) and
neurogenic differentiation factor‐1 and transcription factors for the
development of the endocrine pancreas (Avnit‐Sagi, Vana, & Walker,
2012). The inhibition of miR‐375 has been shown to induce major
defects in pancreatic islet development. So, it has a negative
regulatory role in glucose‐induced insulin secretion. Further, the
high expression of miR‐375 does not affect ATP production or
intracellular calcium, increased by glucose though it influences the
late step in the insulin secretory pathway (Eliasson, 2017; X. Li,
2014). MiR‐375 has been implicated to reduce myotrophin expres-
sion, a route involved in insulin granule fusion, and control insulin
gene expression (Jafarian et al., 2015). MiR‐375 also contributes to
several features of β‐cells, including insulin expression and secretion,
β‐cell proliferation, and adaptation to insulin resistance (Y. Li et al.,
2010). MiR‐375 is expressed in β‐cells and non‐β‐cells islets, where it
might affect glucose homeostasis by inhibiting insulin secretion
(Kloosterman, Lagendijk, Ketting, Moulton, & Plasterk, 2007). In
addition, miR‐375 can regulate the expression of phosphoinositide‐
dependent protein kinase‐1 (PDK1), which relates the PI3 kinase
signaling pathway with the functions of the β‐cell regulator. There-
fore, reduced expression of PDK1 mediated by miR‐375 decreases
insulin gene expression and its secretion (X. Li, 2014; Yan, Lin, &
He, 2014).
6 | OTHER miRNAs INVOLVED
IN INSULIN SECRETION
MiR‐96 has an inhibitory effect on the expression of Granuphilin, an
essential component involved in docking of insulin‐containing
vesicles to the plasma membrane. So, it negatively regulates insulin
exocytosis, by targeting the transcription factor Onecut 2 gene
(W. M. Yang, Min, & Lee, 2016). On the other hand, miR‐96
decreases the expression of the Noc2 gene (Nucleolar complex
protein 2), a Rab GTPase effector that is necessary for insulin
exocytosis (Jeong, Park, Yang, & Lee, 2013). Excess miR‐124a
expression can control several elements of the exocytose pathways
directly or indirectly. Subsequently, it increases the basal insulin
release and decreases the insulin exocytosis pathway. Previous
studies have shown that miR‐124a can suppress Foxa2 (Forkhead
box protein A2) target genes such as the ATP‐sensitive K1 channel
and the transcription factor Pdx‐1. Therefore miR‐124a can be
involved in the regulation of insulin secretion (Jing et al., 2014).
Hyperglycemia can induce hyperexpression of miR‐124a in
pancreatic β‐cells, which impairs insulin secretion after glucose
stimulation. The alterations of miR‐124a expression may con-
tribute to β‐cell dysfunction (de Siqueira et al., 2017). MiRNA‐375
directly regulates insulin secretion through suppressing glucose‐
induced insulin secretion. It targets myotrophin mRNA, which
contributes to adhesion of insulin secretory granules with the
plasma membrane through depolymerization of actin filaments
(Marchand et al., 2016). MiR‐375 can regulate the pathway of
insulin secretion in the pancreatic β‐cells, which is further
modulated by the effects of miR‐124a and miR‐96 on the
components of exocytosis pathways (Chakraborty, Doss,
Bandyopadhyay, & Agoramoorthy, 2014; Ofori, Malm, Mollet,
Eliasson, & Esguerra, 2017). There is evidence showing that
miR‐375 knockout may intensify α cells in pancreatic islets and
gluconeogenesis, leading to elevated plasma glucagon levels and
hepatic glucose output, whereas overexpression of miR‐375
reduces the expression of its targets myotrophin and phosphoi-
nositide‐dependent protein kinase‐1. Overall, miR‐375 is an
essential miRNA for glucose homeostasis, β‐cell proliferation,
and α‐ and β‐cell turnover (Arvidsson et al., 2018; Kloosterman
et al., 2007).
7 | IMPORTANT miRNAs IN TISSUES
There are different miRNAs in peripheral tissue that help improve
insulin functions. Previous research has shown that deregulation of
miRNA expression in the liver may influence glucose homeostasis
and promote progression of diabetes (van de Bunt et al., 2013).
8 | MiRNAs IN LIVER TISSUE
High levels of miR‐122, miR‐192, miR‐148a, and miR‐194 in the liver
are downregulated in hepatocytes, which explains their possible role
in regulating the glucose and metabolism of lipids. One of the most
abundant miRNAs in the liver is miR‐122, which affects hepatocytes
functions (Raitoharju et al., 2014; Thakral & Ghoshal, 2015).
9 | MiRNAs IN ADIPOCYTE TISSUE
On the other hand, miR‐143 is upregulated during human pre-
adipocyte differentiation. It plays an important role in adipocyte
differentiation, lipid metabolism, and adipogenesis (T. Wang
et al., 2011).
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10 | MiRNAs IN MUSCLE TISSUE
Insulin may downregulate 39 different miRNAs in muscle tissue, such
as miR‐1, miR‐206, and miR‐133a/b, which are well‐known miRNAs
for their role in muscle development and growth. Also, miR‐29a and
miR‐29c are highly enriched in insulin‐sensitive tissues (Chien et al.,
2015; Koutsoulidou, Mastroyiannopoulos, Furling, Uney, &
Phylactou, 2011). Evidence has shown that miR‐1 and miR‐133a,
nearly 25% of the total miRNA expression in skeletal muscle,
regulate glucose homeostasis, whereas miR‐133a/b decreases
glucose transporter type 4 expression, leading to a reduction in
insulin‐induced glucose uptake in cardiomyocytes (Katta et al., 2013;
W. Liu et al., 2013). In diabetic cases, miR‐133a/b expression levels
are severely reduced in skeletal muscle, which is associated with
higher fasting glucose levels. Glucose exposure increases miR‐1 and
miR‐133a/b expression levels, which suppress insulin‐like growth
factor‐1 (IGF‐1). IGF‐1 and IGF‐1 receptors are important determi-
nants of insulin sensitivity in muscle tissues (de Gonzalo‐Calvo et al.,
2017; Katta et al., 2013). In addition, miR‐24 and miR‐144 are
involved in insulin sensitivity in muscles, as miR‐24 levels decrease in
diabetic patients. On the other hand, miR‐208a/b and miR‐499 are
expressed in both the heart and the skeletal muscles, excluding
miR‐208a, which is cardiac specific, and miR‐206, which is found only
in skeletal muscle. In the impaired glycemic homeostasis, the
miR‐133a expression alters in the skeletal muscle of diabetic patients
(Caporali, Miscianinov, Saif, & Emanueli, 2016; L. Liu et al., 2018).
11 | MiRNAs IN KIDNEY TISSUE
One of the miRNA family obtained through K‐means clustering is the
kidney‐specific miRNA cluster, which includes miR‐192, miR‐194,
miR‐204, miR‐215, and miR‐216. There were higher levels of these
miRNAs in the renal glomeruli of diabetic rats (Khella et al., 2013;
Warren & Cowan, 2015). MiR‐21 increases in fibrotic kidneys and the
enhanced expression of miR‐21 can upregulate the transforming
growth factor beta 1 (TGF‐β1) or TNF‐α in human renal tubular
epithelial cells (Loboda, Sobczak, Jozkowicz, & Dulak, 2016). MiR‐192
mediates TGF‐β function and plays a major role in kidney develop-
ment and the pathogenesis of DN. On the other hand, TGF‐β1
upregulates miR‐192 expression in cultured glomerular mesangial
cells. In diabetic mice glomeruli, miR‐192 increases the collagen
expression and alters the expression of other renal miRNAs. So,
reducing renal miR‐192 expression decreases renal fibrosis and
improves proteinuria. This supports the possibility of an anti‐miRNA‐
based translational approach for the treatment of DN (A. C. K. Chung,
Huang, Meng, & Lan, 2010; Kato, Dang et al., 2013). MiR‐192 and
miR‐205 are proprietarily expressed in the renal cortex and closely
associated with the pathophysiology of DN. Also, miR‐200c, miR‐141,
miR‐205, and miR‐192 are intimately correlated with disease severity
and progression in patients with IgA nephropathy. Evidence has
shown that miR‐192 and miR‐205 are elevated in the renal tissues of
patients with hypertensive glomerulosclerosis (G. Wang, Kwan, Lai,
Choi et al., 2010; G. Wang, Kwan, Lai, Chow et al., 2010). Moreover,
miR‐377, one of the most abundant miRNAs in DN patients, has
shown to reduce the expressions of p21‐activated kinase‐1 and
superoxide dismutase 1, 2, which enhance fibronectin production.
Consequently, overexpression of miR‐377 in DN indirectly induces
increasing fibronectin production with a critical role in the
pathophysiology of DN (Peng et al., 2017; Q. Wang et al., 2008).
High glucose levels can induce overexpression of miR‐377 in human
mesangial cells, which increases the expression of the matrix
fibronectin protein that causes the progression of DN. Further,
miR‐377 increases the susceptibility to oxidative stress and
accumulation of the extracellular matrix protein in the mesangial
cell in response to high glucose levels (Duan et al., 2017). There are
findings showing that TGF‐β can upregulate miR‐200 and miR‐216
and enhance the accumulation of ECM proteins, such as collagen, in
mouse mesangial cells, which explains its role in the pathogenesis of
DN. On the other hand, TGF‐β upregulates miR‐200b/c and
subsequently downregulates FOG2, which activates the PI3K‐Akt
pathway, responsible for glomerular mesangial hypertrophy (Kato
et al., 2011; Lan, 2012). One of the miRNAs involved in fibrotic
disorders is miR‐21, which regulates fibronectin production by a
transcriptional mechanism in response to high glucose in mesangial
cells. MiR‐21 increases glucose‐induced CREB‐regulated transcrip-
tion coactivator 1 (CRTC1) activity, which results in renal cell
hypertrophy and fibronectin gene expression. On the other hand,
high glucose has a direct impact on phosphatase and tensin homolog
protein (PTEN) downregulation, leading to Akt activation. Thus, miR‐
21 regulates PTEN levels and Akt/CRTC1 activity, which mediates
the pathologic features of diabetic kidney disease (Chau et al., 2012;
Kolling et al., 2017; McClelland et al., 2015). Some studies show an
inverse correlation between miR‐21 expression and PTEN affluence
in type 1 diabetic kidney followed by increased expression of
fibronectin in mesangial cells (Seeger, Fischer, Muhly‐Reinholz,
Zeiher, & Dimmeler, 2014).
12 | MiRNAs AND DN
Recently, a unique class of naturally occurring short noncoding RNA,
called miRNA, has been introduced as important posttranscriptional
regulators of gene expression, which can regulate different biological
functions. Significant attention has also been paid towards the role of
miRNAs as mediators or diagnostic biomarkers for different diseases,
such as DN. MiR‐21 is a central mediator of signal transduction
pathways activating PTEN, Akt, and CRTC1, which is involved in the
pathogenesis of DN; thus targeting miR‐21 can be beneficial for
treating diabetic renal dysfunction (Z. Zhang et al., 2009). There is
evidence suggesting that hyperglycemia induces miR‐21 gene
expression followed by reducing Smad7 abundance and increasing
nuclear factor‐κB (NF‐κB)‐mediated inflammation (Zhong et al.,
2013). On the other hand, miR‐29b plays a protective role in diabetic
kidney diseases and may have therapeutic potential for DN
complications as well (Sun et al., 2017). MiR‐29b has been shown
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to be upregulated in endothelial cells and podocytes under high
glucose conditions. It also might be regulated through the activation
of both TGF‐β/Smad3 and NF‐κB signaling pathways. Improvement of
miR‐29b levels in kidney tissue via gene therapy might block
TGF‐β/Smad3‐mediated kidney fibrosis and NF‐κB renal inflamma-
tion and subsequently inhibit DN (Y. Liu et al., 2010; Sun et al., 2017;
Y. Zhang et al., 2014). MiR‐29b can also regulate inflammatory
process through cytokine expression by T cells mediated through the
Sp1/NF‐κB/miR‐29b regulatory system (H. Y. Chen et al., 2014)
(Figure 2). The majority of miRNAs shown to be beneficial in
nephropathy are regulated through the activation of profibrotic
cytokine TGF‐β (Lee & Choi, 2015). Because of these properties,
miRNAs have been recently considered as diagnostic biomarkers of
DN (Campion, Sanchez‐Ferras, & Batchu, 2017).
13 | GENE THERAPEUTIC IMPACT
OF miRNAs
MiRNAs act at several points in the distinct pathways inducing
insulin secretion or resistance, so they could be potential therapeutic
targets for diabetes (Mirra et al., 2015). Several miRNAs have been
identified in the pathology of DN, and these small molecules have
presented a new possibility for therapeutic intervention (Sethupathy,
2016). Some researchers have attempted to downregulate or
upregulate specific miRNAs using one of several delivery approaches
in animal models of DN. The tendency to control the expression of
miRNAs levels using chemically modified, stable, nuclease‐resistant
oligonucleotides (miRNA inhibitors and mimics) could be developed
for the treatment of patients in the future (Jackson & Linsley, 2010;
Szeto et al., 2012; Y. Zhang et al., 2015). For example, miR‐192 can
control several kidney miRNAs related to DN, so it is a good
candidate target to be evaluated for DN treatment (X. Yang & Liu,
2017). Recently, efficient reduction of miR‐192 was observed in vivo
in normal mice injected with locked nucleic acid (LNA)‐modified anti‐
miR‐192 (Y. Putta et al., 2012).
14 | IMPORTANCE OF miRNAs
FOR CLINICAL PRACTICE
MiRNAs can be considered as potential therapeutic targets for
diabetes, because they are involved in different pathways leading to
insulin secretion or resistance (Hashimoto & Tanaka, 2017). The
recent advances in the technology of miRNA detection and
quantification, including the introduction of microarrays, quantitative
PCRs and next‐generation sequencing, have directed a huge interest
towards developing miRNAs as therapeutic targets and potential
biomarkers for different human diseases. Circulating miRNAs in
blood are found to be sensitive biomarkers for cancer, tissue injury
and heart failure. High levels of miRNAs in urinary sediment have
been reported in patients with IgA nephropathy (Putta et al., 2012).
MiR‐192 is a good target to be considered for the treatment of DN
because it can control other renal miRNAs involved in the
pathogenesis of DN. After the injection of LNA‐modified antimiR‐
192, there was a remarkable reduction in miR‐192 in normal mice in
in vivo conditions (Putta et al., 2012). Different miRNAs have been
recognized to be involved in the pathology of DN, which can be
potentially used for therapeutic intervention in diabetic patients. The
majority of therapeutic studies for miRNAs have looked into their
beneficial impacts on cancer. MiRNAs, which regulate oncogene
F IGURE 2 MiRNA, and insulin
secretion and diabetic nephropathy
progression [Color figure can be viewed at
wileyonlinelibrary.com]
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expression in cancerous cells, are often called oncomiRs. Because of
the complexity of carcinogens, therapies aimed at the suppression of
single oncogenes have shown limited therapeutic response. The same
can be seen in other multifactorial diseases such as DN (Simpson,
Wonnacott, Fraser, & Bowen, 2016). Despite a lot of efforts to
develop more effective drugs to treat DN, not many of these
treatments have met practical requirements. There are ongoing
attempts to address existing gaps including targeting TGF‐β1 or
developing improved protocols for renin‐angiotensin blockade. Still,
new concepts should be investigated to design the most novel and
practical therapies. There is no definite cure for DN; therefore, novel
therapeutic targets are required for preventive and curative
purposes. Dysregulation of miRNA expression has been shown to
contribute to the development of different diseases, including DN; so,
miRNAs are considered feasible targets for therapeutic interven-
tions. Currently, there are three major strategies available for
inactivating miRNAs whose expression is increased in a particular
disease like DN: individual miRNA knockout, sponge miRNA, and
antisense oligonucleotide (DiStefano, Taila, & Alvarez, 2013).
15 | MiRNA AD CANCER
Circulating miRNAs have emerged as excellent candidates for cancer
biomarkers. Several recent studies have highlighted the potential use
of saliva for the identification of miRNAs as novel biomarkers, which
represents a great opportunity to improve diagnosis and monitor
general health and disease. MiRNAs (miRNAs or miRs) constitute one
of the most abundant classes of gene regulatory molecules. Different
mechanisms have been miRNAs deregulation in cancer (Rapado‐
Gonzalez et al., 2018). MiRNAs play a role in cellular functions,
including proliferation, cell cycle control, and programmed cell death,
differentiation, invasiveness, and tissue‐specific functions, such as
immune responses, hormone secretions, and angiogenesis. Genome‐
wide analysis has shown the role of miRNAs expression in cancer
types through mechanisms including defects in the miRNA biogenesis
machinery, amplification/deletion of the region encompassing the
miRNA, or aberrant transcriptional control (Ramassone, Pagotto,
Veronese, & Visone, 2018). The miRNAs play a role in a variety of
biological functions such as cell proliferation, differentiation, apop-
tosis, survival, invasion, and migration. Several studies have demon-
strated mutations in miRNA‐encoding genes or expression of
miRNAs human diseases, including cancers (Lou et al., 2017).
16 | CONCLUSIONS
MiRNAs can play a role in regulating glucose hemostasis, through
modifying β‐cell insulin‐producing function, insulin secretion and
signaling pathways of insulin functions in peripheral tissues such as
the liver, muscle, and adipose tissue. On the other hand, miRNA can
suppress effects of TNF; therefore, the accurate recognition of miRNAs
profiles can help to treat DN, kidney fibrosis, and renal dysfunction.
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